National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.
Takeshi ArashiroSatoru AraiRyo KinoshitaKanako OtaniSho MiyamotoDaisuke YoneokaTaro KamigakiHiromizu TakahashiHiromi HibinoMai OkuyamaAi HayashiFuka KikuchiSaeko MorinoSayaka TakanashiTakaji WakitaKeiko Tanaka-TayaTadaki SuzukiMotoi SuzukiPublished in: Influenza and other respiratory viruses (2023)
Before Omicron, the cumulative burden was >10 times lower in Japan (2.2%) compared with the US (33%), the UK (25%), or global estimates (45%), but most developed antibodies owing to vaccination.